Study of Acarbose in Longevity

Last updated: June 10, 2025
Sponsor: Montefiore Medical Center
Overall Status: Terminated

Phase

2

Condition

Aging

Treatment

Placebo

Acarbose

Clinical Study ID

NCT02953093
2016-6933
  • Ages 60-100
  • Male
  • Accepts Healthy Volunteers

Study Summary

The investigators are studying the effects of acarbose on muscle and adipose gene transcription in older adults.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male

  • age >60 years

  • impaired fasting glucose (IFG) or impaired glucose tolerance (IGT)

Exclusion

Exclusion Criteria:

  • cancer

  • heart failure

  • Chronic Obstructive Pulmonary Disease (COPD)

  • inflammatory conditions

  • estimated Glomerular Filtration Rate (eGFR) <45

  • active liver disease

  • poorly controlled hypertension

  • epilepsy

  • recent cardiovascular disease event (last 6 months)

  • inflammatory bowel disease

  • history of bariatric or other gastric surgery

  • cigarette smoking

  • serious substance abuse.

  • Treatment with drugs known to influence glucose metabolism

  • Hypersensitivity to acarbose or any component of the formulation.

  • Treatment with anti-coagulant medications or anti-platelet drugs

Study Design

Total Participants: 28
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
August 30, 2017
Estimated Completion Date:
December 26, 2019

Study Description

Acarbose, an FDA approved drug for the treatment of type 2 diabetes, has known effects on glucose metabolism. Evidence from mice indicates that acarbose may prolong lifespan. In humans, acarbose improves inflammatory markers and reduces cardiovascular events. Consequently, acarbose is of interest in clinical translational aging research since it may influence fundamental processes that contribute to age-related diseases. The study described herein is an exploratory study to examine the effect of acarbose treatment on the biology of aging in humans. Specifically, the investigators plan to study whether treatment with a 10 week course of acarbose will alter the gene expression profile in adipose tissue and muscle in older adults in pathways that are known to be affected by human aging, in a placebo-controlled crossover study.

Connect with a study center

  • Montefiore Medical Center

    Bronx, New York 10461
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.